{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:47:24Z","timestamp":1793850444626,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Blood Cancer UK 15036"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Incorporating genetics into risk-stratification for treatment of childhood B-progenitor acute lymphoblastic leukaemia (B-ALL) has contributed significantly to improved survival. In about 30% B-ALL (B-other-ALL) without well-established chromosomal changes, new genetic subtypes have recently emerged, yet their true prognostic relevance largely remains unclear. We integrated next generation sequencing (NGS): whole genome sequencing (WGS) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009157) and bespoke targeted NGS (t-NGS) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009175) (overlap\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200936), with existing genetic annotation in a representative cohort of 351 B-other-ALL patients from the childhood ALL trail, UKALL2003.\n                    <jats:italic>PAX5<\/jats:italic>\n                    alt was most frequently observed (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200991), whereas\n                    <jats:italic>PAX5<\/jats:italic>\n                    P80R mutations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911) defined a distinct\n                    <jats:italic>PAX5<\/jats:italic>\n                    subtype.\n                    <jats:italic>DUX4<\/jats:italic>\n                    -r subtype (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200980) was defined by\n                    <jats:italic>DUX4<\/jats:italic>\n                    rearrangements and\/or\n                    <jats:italic>ERG<\/jats:italic>\n                    deletions. These patients had a low relapse rate and excellent survival.\n                    <jats:italic>ETV6::RUNX1<\/jats:italic>\n                    -like subtype (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921) was characterised by multiple abnormalities of\n                    <jats:italic>ETV6<\/jats:italic>\n                    and\n                    <jats:italic>IKZF1<\/jats:italic>\n                    , with no reported relapses or deaths, indicating their excellent prognosis in this trial. An inferior outcome for patients with ABL-class fusions (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200925) was confirmed. Integration of NGS into genomic profiling of B-other-ALL within a single childhood ALL trial, UKALL2003, has shown the added clinical value of NGS-based approaches, through improved accuracy in detection and classification into the range of risk stratifying genetic subtypes, while validating their prognostic significance.\n                  <\/jats:p>","DOI":"10.1038\/s41375-022-01799-4","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T10:02:51Z","timestamp":1671703371000},"page":"529-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial"],"prefix":"10.1038","volume":"37","author":[{"given":"Claire","family":"Schwab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-7724","authenticated-orcid":false,"given":"Ruth E.","family":"Cranston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Winterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Hawking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-1525","authenticated-orcid":false,"given":"Matthew","family":"Bashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-0743","authenticated-orcid":false,"given":"Amir","family":"Enshaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Peden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Barretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-4445","authenticated-orcid":false,"given":"Andrew C.","family":"Hinchliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-4368","authenticated-orcid":false,"given":"Ajay","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-6107","authenticated-orcid":false,"given":"Anthony V.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-6794","authenticated-orcid":false,"given":"Christine J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"1799_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","volume":"11","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97\/99 randomised trial. Lancet Oncol. 2010;11:429\u201338.","journal-title":"Lancet Oncol"},{"key":"1799_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296\u2013307.","journal-title":"Nat Genet"},{"key":"1799_CR3","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li JF, Dai YT, Lilljebjorn H, Shen SH, Cui BW, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA. 2018;115:E11711\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1799_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebjorn","year":"2016","unstructured":"Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.","journal-title":"Nat Commun"},{"key":"1799_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1097\/HS9.0000000000000053","volume":"2","author":"C Schwab","year":"2018","unstructured":"Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics. Hemasphere. 2018;2:e53.","journal-title":"Hemasphere"},{"key":"1799_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"S Hirabayashi","year":"2017","unstructured":"Hirabayashi S, Ohki K, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102:118\u201329.","journal-title":"Haematologica"},{"key":"1799_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13331","volume":"7","author":"Z Gu","year":"2016","unstructured":"Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016;7:13331.","journal-title":"Nat Commun"},{"key":"1799_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3324\/haematol.2017.186320","volume":"104","author":"K Ohki","year":"2019","unstructured":"Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, et al. Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica. 2019;104:128\u201337.","journal-title":"Haematologica"},{"key":"1799_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/gcc.22464","volume":"56","author":"M Zaliova","year":"2017","unstructured":"Zaliova M, Kotrova M, Bresolin S, Stuchly J, Stary J, Hrusak O, et al. ETV6\/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype. Genes Chromosomes Cancer. 2017;56:608\u201316.","journal-title":"Genes Chromosomes Cancer"},{"key":"1799_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016;48:569\u201374.","journal-title":"Nat Genet"},{"key":"1799_CR11","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32:3012\u201320.","journal-title":"J Clin Oncol"},{"key":"1799_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjh.17869","volume":"196","author":"CJ Schwab","year":"2022","unstructured":"Schwab CJ, Murdy D, Butler E, Enshaei A, Winterman E, Cranston RE, et al. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. Br J Haematol. 2022;196:753\u201363.","journal-title":"Br J Haematol"},{"key":"1799_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481\u20139.","journal-title":"Nat Genet"},{"key":"1799_CR14","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","volume":"129","author":"SC Reshmi","year":"2017","unstructured":"Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group. Blood. 2017;129:3352\u201361.","journal-title":"Blood"},{"key":"1799_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22:153\u201366.","journal-title":"Cancer Cell"},{"key":"1799_CR16","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.18632\/oncotarget.13492","volume":"8","author":"JM Boer","year":"2017","unstructured":"Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget. 2017;8:4618\u201328.","journal-title":"Oncotarget"},{"key":"1799_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125\u201334.","journal-title":"Lancet Oncol"},{"key":"1799_CR18","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122:2622\u20139.","journal-title":"Blood"},{"key":"1799_CR19","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","volume":"127","author":"C Schwab","year":"2016","unstructured":"Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood. 2016;127:2214\u20138.","journal-title":"Blood"},{"key":"1799_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood.2020008536","volume":"137","author":"C Schwab","year":"2021","unstructured":"Schwab C, Roberts K, Boer JM, Gohring G, Steinemann D, Vora A, et al. SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood. 2021;137:1835\u20138.","journal-title":"Blood"},{"key":"1799_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjh.17093","volume":"191","author":"AV Moorman","year":"2020","unstructured":"Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol. 2020;191:844\u201351.","journal-title":"Br J Haematol"},{"key":"1799_CR22","doi-asserted-by":"crossref","unstructured":"Ryan SLPJ, Kingsbury Z, Schwab CJ, James T, Polonen P, Butler E, et al. Whole genome sequencing provides comprehensive diagnostic genetic testing in childhood B-cell acute lymphoblastic leukaemia (B-ALL). Leukemia 2022.","DOI":"10.21203\/rs.3.rs-2151721\/v1"},{"key":"1799_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial. Lancet Oncol. 2014;15:809\u201318.","journal-title":"Lancet Oncol"},{"key":"1799_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol. 2013;14:199\u2013209.","journal-title":"Lancet Oncol"},{"key":"1799_CR25","volume-title":"Genomics in the cloud: using Docker, GATK, and WDL in Terra, First edition. edn","author":"GA Van der Auwera","year":"2020","unstructured":"Van der Auwera GA, O\u2019Connor BD, Safari aORMC. Genomics in the cloud: using Docker, GATK, and WDL in Terra, First edition. edn. Sebastopol, CA: O\u2019Reilly Media; 2020."},{"key":"1799_CR26","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754\u201360.","journal-title":"Bioinformatics"},{"key":"1799_CR27","unstructured":"Picard Toolkit. Broad Institute, GitHub Repository. https:\/\/broadinstitute.github.io\/picard\/; Broad Institute. 2019"},{"key":"1799_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsdottir","year":"2013","unstructured":"Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178\u201392.","journal-title":"Brief Bioinform"},{"key":"1799_CR29","doi-asserted-by":"crossref","unstructured":"Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera GA, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv 2018;201178.","DOI":"10.1101\/201178"},{"key":"1799_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"1799_CR31","doi-asserted-by":"publisher","first-page":"W452","DOI":"10.1093\/nar\/gks539","volume":"40","author":"NL Sim","year":"2012","unstructured":"Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: Predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1799_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248\u20139.","journal-title":"Nat Methods"},{"key":"1799_CR33","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","volume":"32","author":"LJ Russell","year":"2014","unstructured":"Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. J Clin Oncol. 2014;32:1453\u201362.","journal-title":"J Clin Oncol"},{"key":"1799_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-59745-418-6_3","volume":"538","author":"ZJ Konn","year":"2009","unstructured":"Konn ZJ, Wright SL, Barber KE, Harrison CJ. Fluorescence In situ hybridization (FISH) as a tool for the detection of significant chromosomal abnormalities in childhood leukaemia. Methods Mol Biol. 2009;538:29\u201355.","journal-title":"Methods Mol Biol"},{"key":"1799_CR35","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/gcc.20818","volume":"49","author":"CJ Schwab","year":"2010","unstructured":"Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:1104\u201313.","journal-title":"Genes Chromosomes Cancer"},{"key":"1799_CR36","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","volume":"124","author":"AV Moorman","year":"2014","unstructured":"Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124:1434\u201344.","journal-title":"Blood"},{"key":"1799_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/gcc.22956","volume":"60","author":"T Creasey","year":"2021","unstructured":"Creasey T, Enshaei A, Nebral K, Schwab C, Watts K, Cuthbert G, et al. Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes, chromosomes cancer. 2021;60:604\u201315.","journal-title":"Genes, chromosomes cancer"},{"key":"1799_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","volume":"98","author":"CJ Schwab","year":"2013","unstructured":"Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica. 2013;98:1081\u20138.","journal-title":"Haematologica"},{"key":"1799_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/bloodadvances.2018025718","volume":"3","author":"L Hamadeh","year":"2019","unstructured":"Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, et al. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Adv. 2019;3:148\u201357.","journal-title":"Blood Adv"},{"key":"1799_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36:1240\u20139.","journal-title":"J Clin Oncol"},{"key":"1799_CR41","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1182\/bloodadvances.2021004895","volume":"5","author":"Z Li","year":"2021","unstructured":"Li Z, Lee SHR, Chin WHN, Lu Y, Jiang N, Lim EH, et al. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. Blood Adv. 2021;5:5226\u201338.","journal-title":"Blood Adv"},{"key":"1799_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease\u2013directed therapy. Blood Cancer Discov. 2021;2:326\u201337.","journal-title":"Blood Cancer Discov"},{"key":"1799_CR43","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3324\/haematol.2018.204487","volume":"104","author":"M Zaliova","year":"2019","unstructured":"Zaliova M, Potuckova E, Hovorkova L, Musilova A, Winkowska L, Fiser K, et al. ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica. 2019;104:1407\u201316.","journal-title":"Haematologica"},{"key":"1799_CR44","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","volume":"35","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Moricke A, et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2021;35:3272\u20137.","journal-title":"Leukemia"},{"key":"1799_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/leu.2013.277","volume":"28","author":"E Clappier","year":"2014","unstructured":"Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28:70\u20137.","journal-title":"Leukemia"},{"key":"1799_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/leu.2013.282","volume":"28","author":"M Zaliova","year":"2014","unstructured":"Zaliova M, Zimmermannova O, Dorge P, Eckert C, Moricke A, Zimmermann M, et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia. 2014;28:182\u20135.","journal-title":"Leukemia"},{"key":"1799_CR47","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2014.142","volume":"28","author":"CH Pui","year":"2014","unstructured":"Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia. 2014;28:2336\u201343.","journal-title":"Leukemia"},{"key":"1799_CR48","doi-asserted-by":"crossref","unstructured":"Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, et al. Time to cure for childhood and young adult acute lymphoblastic leukemia is independent of early risk factors: Long-term follow-up of the UKALL2003 Trial. J Clin Oncol. 2022; JCO2200245.","DOI":"10.1200\/JCO.22.00245"},{"key":"1799_CR49","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","volume":"8","author":"ML den Boer","year":"2021","unstructured":"den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: A multicentre, retrospective, cohort study. Lancet Haematol. 2021;8:e55\u201366.","journal-title":"Lancet Haematol"},{"key":"1799_CR50","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09221.x","volume":"158","author":"A Attarbaschi","year":"2012","unstructured":"Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, et al. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: A comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br J Haematol. 2012;158:772\u20137.","journal-title":"Br J Haematol"},{"key":"1799_CR51","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389.","journal-title":"Nat Genet"},{"key":"1799_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2016.69.6278","volume":"35","author":"D O\u2019Connor","year":"2017","unstructured":"O\u2019Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2017;35:660\u20137.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01799-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T04:29:22Z","timestamp":1678163362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01799-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01799-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2159503\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MTR, DRB, JFP, and ZK are employees of Illumina, a public company that develops and markets systems for genetic analysis. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}